{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:41:59Z","timestamp":1762987319782,"version":"3.45.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jtocrr.2023.100553","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T11:38:48Z","timestamp":1690457928000},"page":"100553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management Paradigm of Central Nervous System Metastases in NSCLC: An Australian Perspective"],"prefix":"10.1016","volume":"4","author":[{"given":"Chee Khoon","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Yang","family":"Soon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalind L.","family":"Jeffree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eng-Siew","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Sen","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hien","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zarnie","family":"Lwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark B.","family":"Pinkham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2023.100553_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/JOP.19.00357","article-title":"Management of brain metastases in non-small-cell lung cancer","volume":"15","author":"Ernani","year":"2019","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.jtocrr.2023.100553_bib2","article-title":"Advances in lung cancer driver genes associated with brain metastasis","volume":"10","author":"Kang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib3","article-title":"Long-term survival of patients with metastatic non-small-cell lung cancer over five decades","volume":"2021","author":"Bar","year":"2021","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib4","first-page":"23","article-title":"Toward the complete control of brain metastases using surveillance screening and stereotactic radiosurgery","volume":"128","author":"Wolf","year":"2018","journal-title":"J\u00a0Neurol Surg"},{"key":"10.1016\/j.jtocrr.2023.100553_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","article-title":"Radiation therapy for brain metastases: an ASTRO clinical practice guideline","volume":"12","author":"Gondi","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib7","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3332\/ecancer.2020.1136","article-title":"Multidisciplinary brain metastasis clinic: is it effective and worthwhile?","volume":"14","author":"Rajpurohit","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.jtocrr.2023.100553_bib8","first-page":"162","article-title":"Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)","volume":"19","author":"Soffietti","year":"2017","journal-title":"Neurooncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13014-016-0653-3","article-title":"Hypo-fractionated stereotactic radiotherapy alone using volumetric modulated arc therapy for patients with single, large brain metastases unsuitable for surgical resection","volume":"11","author":"Navarria","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib10","doi-asserted-by":"crossref","first-page":"e874","DOI":"10.1016\/j.wneu.2018.05.120","article-title":"Very large metastases to the brain: retrospective study on outcomes of surgical management","volume":"116","author":"Gattozzi","year":"2018","journal-title":"World Neurosurg"},{"key":"10.1016\/j.jtocrr.2023.100553_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10072-017-3220-2","article-title":"Multiple brain metastases: a surgical series and neurosurgical perspective","volume":"39","author":"Salvati","year":"2018","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jtocrr.2023.100553_bib12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199002223220802","article-title":"A\u00a0randomized trial of surgery in the treatment of single metastases to the brain","volume":"322","author":"Patchell","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2023.100553_bib13","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1245\/s10434-016-5709-y","article-title":"Surgical resection of cerebral metastases leads to faster resolution of peritumoral edema than stereotactic radiosurgery: a volumetric analysis","volume":"24","author":"Shimony","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib14","first-page":"730","article-title":"Reduced local recurrence of a single brain metastasis through microscopic total resection","volume":"110","author":"Yoo","year":"2009","journal-title":"J\u00a0Neurol Surg"},{"key":"10.1016\/j.jtocrr.2023.100553_bib15","first-page":"181","article-title":"Factors influencing the risk of local recurrence after resection of a single brain metastasis","volume":"113","author":"Patel","year":"2010","journal-title":"J\u00a0Neurol Surg"},{"key":"10.1016\/j.jtocrr.2023.100553_bib16","first-page":"1132","article-title":"Impact of surgical methodology on the complication rate and functional outcome of patients with a single brain metastasis","volume":"122","author":"Patel","year":"2015","journal-title":"J\u00a0Neurol Surg"},{"key":"10.1016\/j.jtocrr.2023.100553_bib17","unstructured":"National Comprehensive Cancer Network\u00ae (NCCN\u00ae). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Central Nervous System Cancers. version 2.2021. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1425. Accessed December 8, 2021."},{"key":"10.1016\/j.jtocrr.2023.100553_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.radonc.2018.12.018","article-title":"Volume not number of metastases: gamma Knife radiosurgery management of intracranial lesions from an Australian perspective","volume":"133","author":"Izard","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib20","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2023.100553_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1754-9485.12942","article-title":"Contemporary practice patterns of stereotactic radiosurgery for brain metastasis: a review of published Australian literature","volume":"63","author":"Ong","year":"2019","journal-title":"J\u00a0Med Imaging Radiat Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11060-017-2442-8","article-title":"The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies","volume":"133","author":"Kim","year":"2017","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3389\/fonc.2018.00395","article-title":"Diagnosis and management of radiation necrosis in patients with brain metastases","volume":"8","author":"Vellayappan","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.radonc.2020.10.043","article-title":"Role of radiotherapy in the management of brain metastases of NSCLC - decision criteria in clinical routine","volume":"154","author":"Glatzer","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib26","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11060-020-03542-4","article-title":"Prescription of memantine during non-stereotactic, brain-directed radiation among patients with brain metastases: a population-based study","volume":"148","author":"Lamba","year":"2020","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2004.05.128","article-title":"Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial","volume":"22","author":"Meyers","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211034269","article-title":"The effect of hippocampal avoidance whole brain radiotherapy on the preservation of long-term neurocognitive function in non-small cell lung cancer patients with brain metastasis","volume":"20","author":"Wang","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.jtocrr.2023.100553_bib29","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001","volume":"38","author":"Brown","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib30","first-page":"CD009454","article-title":"Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases","volume":"2014","author":"Soon","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtocrr.2023.100553_bib31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jtocrr.2023.100553_bib32","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC.3): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib33","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1634\/theoncologist.2017-0572","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for central nervous system metastases from non-small cell lung cancer","volume":"23","author":"Ahluwalia","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jtocrr.2023.100553_bib34","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2023.100553_bib35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical Comparison of the blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2023.100553_bib36","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2016.69.7144","article-title":"Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis","volume":"35","author":"Magnuson","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib37","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.3390\/cancers13225823","article-title":"Oligoprogression in non-small cell lung cancer","volume":"13(22)","author":"Harada","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2023.100553_bib38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib39","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.lungcan.2013.07.025","article-title":"Genetic alterations defining NSCLC subtypes and their therapeutic implications","volume":"82","author":"Pikor","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2023.100553_bib40","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/1078-0432.CCR-10-1591","article-title":"Targeting anaplastic lymphoma kinase in lung cancer","volume":"17","author":"Shaw","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2023.100553_bib41","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated OS and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib42","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","article-title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study","volume":"29","author":"Gadgeel","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib43","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.20.00505","article-title":"Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial","volume":"38","author":"Camidge","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib44","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-Positive non-small-Cell Lung Cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2023.100553_bib45","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib46","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non\u2013small-cell lung cancer from the phase III CROWN study","volume":"40(31)","author":"Solomon","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib47","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 4","key":"10.1016\/j.jtocrr.2023.100553_bib48","doi-asserted-by":"crossref","first-page":"S1180","DOI":"10.1016\/j.annonc.2020.08.2282","article-title":"LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): results of the phase III crown study","volume":"31","author":"Solomon","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib49","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jtho.2020.12.022","article-title":"Lorlatinib should not be considered as the preferred first-line option in patients with advanced ALK rearranged NSCLC","volume":"16","author":"Camidge","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"4","key":"10.1016\/j.jtocrr.2023.100553_bib50","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/ijms21041416","article-title":"Brain metastases in lung cancers with emerging targetable fusion drivers","volume":"21","author":"Tan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtocrr.2023.100553_bib51","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12916-021-02082-6","article-title":"Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study","volume":"19","author":"Zhang","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.jtocrr.2023.100553_bib52","first-page":"17","article-title":"Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? Precis","volume":"3","author":"Sehgal","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtocrr.2023.100553_bib53","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920980558","article-title":"Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program","volume":"13","author":"Frost","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib54","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-19-2777","article-title":"Repotrectinib exhibits potent antitumor activity in treatment-naive and solvent-front-mutant ROS1-rearranged non-small cell lung cancer","volume":"26","author":"Yun","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2023.100553_bib55","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive non-small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2023.100553_bib56","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2023.100553_bib57","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib58","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10 suppl","key":"10.1016\/j.jtocrr.2023.100553_bib59","doi-asserted-by":"crossref","first-page":"S862","DOI":"10.1016\/j.jtho.2021.08.061","article-title":"OA09.01 first-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and brain metastases: results from CheckMate 9LA","volume":"16","author":"Carbone","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"suppl 7","key":"10.1016\/j.jtocrr.2023.100553_bib60","doi-asserted-by":"crossref","first-page":"S1430","DOI":"10.1016\/j.annonc.2021.10.141","article-title":"122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): intracranial and systemic outcomes from CheckMate 227 Part 1","volume":"32","author":"Reck","year":"2021","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.jtocrr.2023.100553_bib61","article-title":"Updated analysis from the ATEZO-BRAIN trial: atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non\u2013small cell lung cancer with untreated brain metastases","volume":"40","author":"Nadal","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib62","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/cncr.21322","article-title":"Leptomeningeal metastases from small cell lung carcinoma","volume":"104","author":"Seute","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2023.100553_bib63","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3389\/fonc.2019.01224","article-title":"Radiotherapy in leptomeningeal disease: a systematic review of randomized and non-randomized trials","volume":"9","author":"Buszek","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib64","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/S1470-2045(17)30689-7","article-title":"Leptomeningeal metastases in non-small-cell lung cancer","volume":"19","author":"Cheng","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib65","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jocn.2017.12.009","article-title":"Postoperative radiosurgery for the treatment of metastatic brain tumor: evaluation of local failure and leptomeningeal disease","volume":"49","author":"Foreman","year":"2018","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.jtocrr.2023.100553_bib66","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijrobp.2015.11.022","article-title":"Surgical resection of brain metastases and the risk of leptomeningeal recurrence in patients treated with stereotactic radiosurgery","volume":"94","author":"Johnson","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtocrr.2023.100553_bib67","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11060-017-2666-7","article-title":"Risk of leptomeningeal carcinomatosis in patients with brain metastases treated with stereotactic radiosurgery","volume":"136","author":"Ma","year":"2018","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib68","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib69","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11060-014-1539-6","article-title":"Risk factors for leptomeningeal carcinomatosis in patients with brain metastases who have previously undergone stereotactic radiosurgery","volume":"120","author":"Huang","year":"2014","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib70","first-page":"1049","article-title":"A\u00a0multi-institutional analysis of presentation and outcomes for leptomeningeal disease recurrence after surgical resection and radiosurgery for brain metastases","volume":"21","author":"Prabhu","year":"2019","journal-title":"Neurooncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib71","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1186\/s12885-021-08581-2","article-title":"Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtocrr.2023.100553_bib72","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib73","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fonc.2018.00278","article-title":"Management of leptomeningeal metastases in non-oncogene addicted non-small cell lung cancer","volume":"8","author":"Turkaj","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2023.100553_bib74","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain Metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jtocrr.2023.100553_bib75","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952\u201326001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J\u00a0Clin Oncol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364323000966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364323000966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:38:41Z","timestamp":1762987121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364323000966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":74,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2666364323000966"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100553","relation":{},"ISSN":["2666-3643"],"issn-type":[{"type":"print","value":"2666-3643"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management Paradigm of Central Nervous System Metastases in NSCLC: An Australian Perspective","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100553"}}